Nonlinear quantitative structure-activity relationship for the inhibition of dihydrofolate reductase by pyrimidines

Journal of Medicinal Chemistry

Volumn 39, Issue 18, 1996, Pages 3526-3532

  Hirst, Jonathan D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 5 BENZYLPYRIMIDINE DERIVATIVE; ANTIINFECTIVE AGENT; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR;

ALGORITHM; ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; ENZYME INHIBITION; ESCHERICHIA COLI; NONHUMAN; NONLINEAR SYSTEM; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ESCHERICHIA COLI; FOLIC ACID ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029795419     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960197z     Document Type: Article

References (32)

1. Hansch, C.; Maloney, P. P.; Fujita, T.; Muir, R. M. Correlation of biological activity of phenoxyacetic acids with Hammett substitution constants and partition coefficients. Nature 1962, 194, 178-180.
2. Hanscb, C. A quantitative approach to biochemical structure-activity relationships. Acc. Chem. Res. 1969, 2, 232-239.
3. Andrea, T. A.; Kalayeh, H. Applications of neural networks in quantitative structure-activity relationships of dihydrofolate reductase inhibitors. J. Med. Chem. 1991, 34, 2824-2836.
4. So, S.-S.; Richards, W. G. Application of neural networks: quantitative structure-activity relationships of the derivatives of 2,4-diamino-5-(substituted-benzyl)pyrimidines as DHFR inhibitors. J. Med. Chem. 1992, 35, 3201-3207.
5. Villemin, D.; Cherqaoui, D.; Cense, J. M. Neural network studies: quantitative structure-activity relationship of mutagenic aromatic nitro compounds. J. Chim. Phys. 1993, 90, 1505-1519.
6. Ajay. A unified framework for using neural networks to build QSARs. J. Med. Chem. 1993, 36, 3565-3571.
7. King, R. D.; Hirst, J. D.; Sternberg, M. J. E. New approaches to QSAR: Neural networks and machine learning. Perspect. Drug Discovery Des. 1993, 1, 279-290.
8. Hirst, J. D.; King, R. D.; Sternberg, M. J. E. Quantitative structure-activity relationships by neural networks and inductive logic programming I. The inhibition of dihydrofolate reductase by pyrimidines. J. Comput.-Aided Mol. Des. 1994, 8, 405-420.
9. Hirst, J. D.; King, R. D.; Sternberg, M. J. E. Quantitative structure-activity relationships by neural networks and inductive logic programming II. The inhibition of dihydrofolate reductase by triazines. J. Comput.-Aided Mol. Des. 1994, 8, 421-432.
10. Tetko, I. G.; Tanchuk, V. Y.; Chentsova, N. P.; Antonenko, S. V.; Poda, G. I.; Kukhar, V. P.; Luik, A. I. HIV-1 reverse transcriptase inhibitor design using artificial neural networks. J. Med. Chem. 1994, 37, 2520-2526.
11. Manallack, D. T.; Ellis, D. D.; Livingstone, D. J. Analysis of linear and nonlinear QSAR data using neural networks. J. Med. Chem. 1994, 37, 3758-3767.
12. Ajay. On better generalization by combining two or more models: A quantitative structure-activity relationship example using neural networks. Chem. Intell. Lab. Systems 1994, 24, 19-30.
13. Maddalena, D. J.; Johnston, G. A. R. Prediction of receptor properties an binding affinity of ligands to benzodiazepine/ GABAA receptors using artificial neural networks. J. Med. Chem. 1995, 38, 715-724.
14. Bolis, G.; Pace, L. D.; Fabrocini, F. A machine learning approach to computer-aided molecular design. J. Comput.-Aided. Mol. Des. 1991, 5, 617-628.
15. King, R. D.; Muggleton, S.; Lewis, R. A.; Sternberg, M. J. E. Drug design by machine learning: the use of inductive logic programming to model the structure-activity relationships of trimethoprim analogues binding to dihydrofolate reductase. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11322-11326.
16. King, R. D.; Muggleton, S. H.; Srinivasan, A.; Sternberg, M. J. E. Structure-activity relationships derived by machine learning: The use of atoms and their bond connectivities to predict mutagenicity by inductive logic programming. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 438-442.
17. Jain, A. N.; Dietterich, T. G.; Lathrop, R. H.; Chapman, D.; Critchlow, R. E.; Bauer, B. E.; Webster, T. A.; Lozano-Perez, T. Compass: A shape-based machine learning tool for drug design. J. Comput.-Aided Drug Des. 1994, 8, 635-652.
18. Jackson, R. C. Update on computer-aided drug design. Curr. Opin. Biotech. 1995, 6, 646-651.
19. Champness, J. N.; Stammers, D. K.; Beddell, C. R. Crystallographic investigation of the cooperative interaction between trimethoprim, reduced cofactor and dihydrofolate reductase. FEBS Letts. 1986, 199, 61-67.
20. Matthews, D. A.; Bolin, J. T.; Burridge, J. M.; Filman, D. J.; Volz, K. W.; Kaufman, B. T.; Beddell, C. R.; Champness, J. N.; Stammers, D. K.; Kraut, J. Refined crystal structures of Escherichia coli and chicken liver dihydrofolate reductase containing bound trimethoprim. J. Biol. Chem. 1985, 260, 381-391.
21. Li, R. L.; Dietrich, S. W.; Hansch, C. Quantitative structure-selectivity relationships. Comparison of the inhibition of Escherichia coli and bovine liver dihydrofolate reductase by 5-(substituted-benzyl)-2,4-diaminopyrimidines. J. Med. Chem. 1981, 24, 538-544.
22. Selassie, C. D.; Li, R.-L.; Poe, M.; Hansch, C. On the optimization of hydrophobic and hydrophilic substituent interactions of 2,4-diamino-5-(substituted benzyl)pyrimidines with dihydrofolate reductase. J. Med. Chem. 1991, 34, 46-54.
23. Roth, B.; Aig, E.; Rauckman, B. S.; Srelitz, J. Z.; Phillips, A. P.; Ferone, R.; Bushby, S. R. M.; Siegel, C. W. 2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 5. 3′,5′-Dimethoxy-4′-substituted-benzyl analogues of trimethoprim. J. Med. Chem. 1981, 24, 933-941.
24. Roth, B.; Rauckman, B. S.; Ferone, R.; Baccanari, D. P.; Champness, J. N.; Hyde, R. M. 2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 7. Analysis of the effect of 3,5-dialkyl substituent size and shape on binding to four different dihydrofolate reductase enzymes. J. Med. Chem. 1987, 30, 348-356.
25. King, R. D.; Hirst, J. D.; Sternberg, M. J. E. Comparison of artificial intelligence methods for modeling pharmaceutical QSARs. Appl. Artif. Intell. 1995, 9, 213-234.
26. Gallop, M. A.; Barrett, R. W.; Dower, W. J.; Fodor, S. P. A.; Gordon, E. M. Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. J. Med. Chem. 1994, 37, 1233-1251.
27. Gordon, E. M.; Barrett, R. W.; Dower, W. J.; Fodor, S. P. A.; Gallop, M. A. Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions. J. Med. Chem. 1994, 37, 1385-1401.
28. Hansch, C.; Li, R.-I.; Blaney, J. M.; Langridge, R. Comparison of the inhibition of Escherichia coli and Lactobacillus casei dihydrofolate reductase by 2,4-diamino-5-(substituted-benzyl)-pyrimidines: quantitative structure-activity relationships, X-ray crystallography, and computer graphics in structure-activity analysis. J. Med. Chem. 1982, 25, 777-784.
29. Franke, R. Theoretical Drug Design Methods; Elsevier: Amsterdam, 1984.
30. Quinlan, J. Induction of decision trees. Machine Learning 1986, 1, 81-106.
31. Breiman, L.; Friedman, J. H.; Olshen, R. A.; Stone, C. J. Classification and Regression Trees; Wadsworth: Belmont, 1984.
32. Muggleton, S.; Feng, C. Efficient induction of logic programs. In Proceedings of the First Conference on Algorithmic Learning Theory; Arikawa, S., Goto, S., Ohsuga, S., Yokomori, T., Eds.; Jpn. Soc. Artificial Intelligence: Tokyo, 1990; pp 368-381.